Crossmark

Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Crossref DOI link: https://doi.org/10.1007/s40801-024-00477-4

Published Online: 2025-01-16

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fautrel, Bruno https://orcid.org/0000-0001-8845-4274
Bouhnik, Yoram https://orcid.org/0000-0002-5787-4943
Salliot, Carine https://orcid.org/0000-0003-1066-4161
Carbonnel, Franck https://orcid.org/0000-0002-4779-5168
Fumery, Mathurin

Bernardeau, Christophe https://orcid.org/0000-0002-2337-2902
Maugars, Yves https://orcid.org/0000-0002-5131-8524
Flamant, Mathurin https://orcid.org/0000-0002-8076-7046
Coury, Fabienne https://orcid.org/0000-0002-9175-8620
Braithwaite, Ben https://orcid.org/0000-0002-7378-1034
Hateb, Salima

Addison, Janet

,
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

First Online: 16 January 2025